The two biggest breast cancer risk factors for women are being a woman and aging. In this episode, we dive into the science behind how menopause impacts breast cancer risk, explore lifestyle factors such as diet, exercise, and alcohol consumption that may contribute to breast health, and discuss the importance of regular screenings, early detection, and genetics.Whether you’re navigating perimenopause, post-menopause, or anywhere in between, our goal is to provide clear, practical information to help you manage your health with confidence. We discuss the following topics: -breast cancer risk factors -when and why to test genetics associated with breast cancer and inflammation -looking at lab biomarkers to assess risk -how poor lifestyle habits increase risk -mammograms, ultrasounds, and MRI's for screening -Ashkenazi Jewish women and breast cancer risk - the POWER-Remote Trial for breast cancer using health coaching: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299780/ -how GLP-1 agonists play a role in reducing cancer risk Medical Disclaimer: By listening to this podcast, you agree not to use this podcast as medical advice or to make any lifestyle changes to treat any medical condition in yourself or others. Consult your physician for any medical issues that you may be having. This entire disclaimer also applies to any of my guests on my podcast. Today my guest is Dr. Vered Stearns, Director, of Women’s Malignancies Disease Group, Medical Director, Under Armour Breast Health Innovation Center, Professor of Oncology, Breast Cancer Research Chair in Oncology, Assistant Director for Faculty Affairs, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine. Dr. Stearn shares her expertise on lifestyle interventions that reduce your risk of developing breast cancer. Dr. Stearns’ clinical research has focused on improving current therapies by individualizing strategies for the treatment and prevention of breast cancer. She was among the first to evaluate the role of specific cancer-related genetic mutations in breast cancer survivors who had been treated with tamoxifen to prevent the reoccurrence of the disease. She also has led similar research on the association between genetic mutations and outcomes for women treated with aromatase inhibitors, a class of drugs used to treat breast cancer in post-menopausal women. Among her many honors, Dr. Stearns was selected by Forbes in 2017 as one of the 27 top breast cancer oncologists in the country. In 2022, Dr. Stearns received the Kimmel Cancer Center Mentoring Award in recognition of her dedication to trainees and faculty members. Dr. Stearns joins Weill-Cornell Medicine as Director of Translational Breast Cancer in the Department of Medicine and Associate Director for Clinical Affairs at the Meyer Cancer Center. In her new role, she looks forward to developing programs and mentoring team members across cancer types at sites in Manhattan, Brooklyn, and Queens. Follow me on Instagram: https://www.instagram.com/jillfooswellness/ Follow me on Facebook: https://www.facebook.com/jillfooswellness Grab discounts on my favorite biohacking products: https://www.jillfooswellness.com/health-products Enjoy 20% savings and free shipping at Fullscript for your favorite supplements by leading brands: https://us.fullscript.com/welcome/jillfooswellness Subscribe to the JFW newsletter at www.jillfooswellness.com and receive your FREE Guide on How To Increase Your Protein in 5 Easy Steps and your free Protein Powder Recipe Ebook. Schedule your complimentary 30-minute Zoom consultation here: https://calendly.com/jillfooswellness/30-minute-zoom-consultations

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related